MLTX: MoonLake Immunotherapeutics Stock

by  •  • Comments Off on MLTX: MoonLake Immunotherapeutics Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,656.45
Enterprise Value ($M) 2,223.10
Book Value ($M) 513.49
Book Value / Share 8.17
Price / Book 5.17
NCAV ($M) 501.12
NCAV / Share 7.97
Price / NCAV 5.30

Profitability (mra)
Return on Invested Capital (ROIC) -0.07
Return on Assets (ROA) -0.54
Return on Equity (ROE) -0.61

Liquidity (mrq)
Quick Ratio 51.59
Current Ratio 51.59

Balance Sheet (mrq) ($M)
Current Assets 514.17
Assets 526.54
Liabilities 13.05
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -54.12
Net Income -36.01

Cash Flow Statement (mra) ($M)
Cash From Operations -42.78
Cash from Investing -25.18
Cash from Financing 479.70

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-05 13D/A Biotechnology Value Fund L P 34.60 0.00
02-14 13G/A Chen Bihua 14.17 23.24
02-14 13G/A Citadel Advisors Llc 3.40
02-09 13G Fmr Llc 6.42 222.52

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 30,140 206,193 14.62
2024-04-25 60,188 264,856 22.72
2024-04-24 49,494 61,261 80.79
2024-04-23 61,040 117,154 52.10

(click for more detail)

Similar Companies
MBRX – Moleculin Biotech, Inc. MEIP – MEI Pharma, Inc.
MIRA – MIRA Pharmaceuticals, Inc. MNPR – Monopar Therapeutics Inc.
MRKR – Marker Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io